ReviewPharmaceuticals (Basel, Switzerland)2017
The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications.
Review in Pharmaceuticals (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- Hormonally and chemically defined expansion conditions for organoids of biliary tree Stem Cells.Bioactive materials · 2024Article
- Enhancing diabetic foot ulcer healing: Impact of the regulation of the FUS and ILF2 RNA‑binding proteins through negative pressure wound therapy.International journal of molecular medicine · 2024Article
- The development of a nucleus pulposus-derived cartilage analog scaffold for chondral repair and regeneration.Journal of biomedical materials research. Part A · 2024Article
- Carbohydrate based biomaterials for neural interface applications.Journal of materials chemistry. B · 2022Review
- High sensitivity analysis of nanogram quantities of glycosaminoglycans using ToF-SIMS.Communications chemistry · 2021Article
- A Biomimetic Approach toward Enhancing Angiogenesis: Recombinantly Expressed Domain V of Human Perlecan Is a Bioactive Molecule That Promotes Angiogenesis and Vascularization of Implanted Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Glycosaminoglycan-based biomaterials for growth factor and cytokine delivery: Making the right choices.Journal of controlled release : official journal of the Controlled Release Society · 2019Review
- Fully Synthetic Heparan Sulfate-Based Neural Tissue Construct That Maintains the Undifferentiated State of Neural Stem Cells.ACS chemical biology · 2019Article
- Efficient Synthesis of Heparinoid Bioconjugates for Tailoring FGF2 Activity at the Stem Cell-Matrix Interface.Bioconjugate chemistry · 2019Article
- Biologic canine and human intervertebral disc repair by notochordal cell-derived matrix: from bench towards bedside.Oncotarget · 2018Article
- Guided bone regeneration using a bone tissue engineering complex consisting of a poly-Oncotarget · 2018Article
- Glycosaminoglycans and Proteoglycans.Pharmaceuticals (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
High sulfation, low cost, and the status of heparin as an already FDA- and EMA- approved product, mean that its inclusion in tissue engineering (TE) strategies is becoming increasingly popular. However, the use of heparin may represent a naïve approach. This is because tissue formation is a highly orchestrated process, involving the temporal expression of numerous growth factors and complex signaling networks. While heparin may enhance the retention and activity of certain growth factors under particular conditions, its binding 'promiscuity' means that it may also inhibit other factors that, for example, play an important role in tissue maintenance and repair. Within this review we focus on articular cartilage, highlighting the complexities and highly regulated processes that are involved in its formation, and the challenges that exist in trying to effectively engineer this tissue. Here we discuss the opportunities that glycosaminoglycans (GAGs) may provide in advancing this important area of regenerative medicine, placing emphasis on the need to move away from the common use of heparin, and instead focus research towards the utility of specific GAG preparations that are able to modulate the activity of growth factors in a more controlled and defined manner, with less off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.